SEK1/MKK4 (Ab-80) Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-SEK1/MKK4 (Ab-80) antibody, protein, ELISA kits.

Edit 
Antigenic SpecificitySEK1/MKK4 (Ab-80)
Clonepolyclonal
Host Speciesn/a
Reactive Specieshuman, mouse, rat
Isotypen/a
Formatimmunogen affinity purified
Size0.05 mg, 0.1 mg
Concentrationn/a
ApplicationsWestern Blot (WB), Immunohistochemistry (IHC)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionSpecificity: SEK1/MKK4 (Ab-80) antibody detects endogenous levels of total SEK1/MKK4 protein.
ImmunogenImmunogen: The antiserum was produced against synthesized non-phosphopeptide derived from human SEK1/MKK4 around the phosphorylation site of serine 80 (T-H-SP-I-E).
Other Names[dual specificity mitogen-activated protein kinase kinase 4 isoform 2; Dual specificity mitogen-activated protein kinase kinase 4; dual specificity mitogen-activated protein kinase kinase 4; mitogen-activated protein kinase kinase 4; JNK-activating kinase 1; MAPK/ERK kinase 4; MEK 4; SAPK/ERK kinase 1; SEK1; Stress-activated protein kinase kinase 1; SAPK kinase 1; SAPKK-1; SAPKK1; c-Jun N-terminal kinase kinase 1; JNKK], [MAP2K4; MAP2K4; JNKK; MEK4; MKK4; SEK1; SKK1; JNKK1; SERK1; MAPKK4; PRKMK4; SAPKK1; SAPKK-1; JNKK1; MEK4; MKK4; PRKMK4; SEK1; SERK1; SKK1; MAP kinase kinase 4; MAPKK 4; MEK 4; SEK1; SAPK kinase 1; SAPKK-1; SAPKK1; JNKK]
Gene, Accession #[SEK1/MKK4], Gene ID: 6416, NCBI: NP_001268364.1, UniProt: P45985
Catalog #MBS856712
Price$170, $230
Order / More InfoSEK1/MKK4 (Ab-80) Antibody from MYBIOSOURCE INC.
Product Specific ReferencesPark HS, et al. (2002) J Biol Chem; 277(4): 2573-8.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.